Lonza Group AG (VIE:LONN)
Austria
· Delayed Price · Currency is EUR | Market Cap | 41.45B |
| Revenue (ttm) | 7.01B |
| Net Income (ttm) | 1.02B |
| Shares Out | n/a |
| EPS (ttm) | 14.51 |
| PE Ratio | 40.66 |
| Forward PE | 29.35 |
| Dividend | 4.27 (0.72%) |
| Ex-Dividend Date | May 13, 2025 |
| Volume | n/a |
| Average Volume | 1 |
| Open | 585.80 |
| Previous Close | 580.80 |
| Day's Range | 585.80 - 590.20 |
| 52-Week Range | 549.60 - 633.60 |
| Beta | n/a |
| RSI | 56.53 |
| Earnings Date | Apr 1, 2026 |
About Lonza Group AG
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics; Small Molecules; Cell & Gene; and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substanc... [Read more]
Financial Performance
In 2025, Lonza Group AG's revenue was 6.53 billion, a decrease of -0.65% compared to the previous year's 6.57 billion. Earnings were 949.00 million, an increase of 49.21%.
Financial numbers in CHF Financial StatementsNews
Lonza Group Continues To Leverage Biopharma's Optimization Push
Lonza Group remains a leading CDMO, capitalizing on biopharma's shift to outsourced manufacturing and complex drug production. LZAGY delivered strong H2 results: 17% CDMO revenue growth, 28% EBITDA gr...
Lonza Group AG (LZAGY) Q4 2025 Earnings Call Transcript
Lonza Group AG (LZAGY) Q4 2025 Earnings Call Transcript
Lonza Group AG (LZAGY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Lonza Group AG (LZAGY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Lonza Group AG (LZAGY) Q3 2025 Earnings Call Transcript
Lonza Group AG (OTCPK:LZAGY) Q3 2025 Earnings Call October 23, 2025 8:00 AM EDT Company Participants Philippe Deecke - Chief Financial Officer Conference Call Participants Zain Ebrahim - JPMorgan Chas...
Lonza Group AG (LZAGY) Q2 2025 Earnings Call Transcript
Lonza Group AG (OTCPK:LZAGY) Q2 2025 Earnings Conference Call July 23, 2025 8:00 AM ET Company Participants Philippe Deecke - Chief Financial Officer Wolfgang Wienand - Chief Executive Officer Confere...
Lonza Group AG (LZAGY) Q1 2025 Earnings Call Transcript
Lonza Group AG (OTCPK:LZAGY) Q1 2025 Earnings Conference Call May 9, 2025 9:00 AM ET Company Participants Philippe Deecke - Chief Financial Officer Conference Call Participants Zain Ebrahim - JPMorgan...
Lonza: Well Equipped In The U.S., Buy Confirmed
Sustainable high market growth ahead with supportive margin recovery. There are limited tariff risks. Lonza is a potential beneficiary given the ample availability of the USA industrial capacities sho...
Lonza Group AG (LZAGY) Q2 2024 Earnings Call Transcript
Lonza Group AG (OTCPK:LZAGY) Q2 2024 Earnings Conference Call July 25, 2024 7:00 AM ET Company Participants Wolfgang Wienand - Chief Executive Officer Philippe Deecke - Chief Financial Officer Confere...
LZAGY, DSDVY: Investment Opportunities Outside of the U.S.
U.S. equity markets have benefitted from a perceived quality advantage over Europe, though it's uncertain when outperformance will end, notes Bryan Lee. He discusses finding investment opportunities o...
Lonza Group AG (LZAGY) Q1 2024 Earnings Call Transcript
Lonza Group AG (OTCPK:LZAGY) Q1 2024 Earnings Conference Call May 14, 2024 8:00 AM ET Company Participants Albert Baehny - Interim Chief Executive Officer & Chairman of the Board of Directors Philippe...
Lonza: Acceleration In Mid-Term Sales Growth
Reflecting Lonza's Vacaville acquisition, we increased our sales and EBITDA expectations. The company has an ongoing buyback and a progressive dividend per share. We positively view the new CEO appoin...
Lonza: Excellent Growth Projections Will Sharply Increase Free Cash Flow
Lonza Group aims to increase revenue by double digits by 2028 through aggressive expansion in the CDMO space. Lonza expects to increase its EBITDA margin to 32%-34% by 2028 and maintain a low debt rat...
Lonza Group AG (LZAGY) Q4 2023 Earnings Call Transcript
Lonza Group AG (LZAGY) Q4 2023 Earnings Call Transcript
Lonza chairman to step down, drugmaker confirms targets, shares soar
Lonza said on Friday Chairman Albert Baehny will step down in May after six years in the job, in a second senior management reshuffle in recent months as the Swiss contract drug manufacturer grapples ...
Lonza: The Day Has Come, And We Lower Our Expectation
Here at the Lab, post Capital Market Day, we are in a show-me-story scenario. Moderna contract termination is a positive short-term catalyst; however, it is an adverse concern over the biotech sector'...
Lonza Group: Downside Scenario Already Priced In
Lonza's CEO departure raises questions about business continuity, but we believe the stock price already reflects the worst-case scenario. Lower CAPEX and an ongoing buyback program (with potential M&...
Lonza CEO departure prompts concern over earnings prospects
Contract drug manufacturer Lonza said on Monday Chief Executive Pierre-Alain Ruffieux will leave the Swiss company by mutual agreement at the end of the month, weighing on investor confidence about th...
Biopharma Bounce-Back: From Policy Pains To Profitable Plains
The recent IRA list of 10 drug publications is not expected to have a significant impact on big pharma stocks in the near term. The legal challenges by big pharma companies against the IRA may derail ...
Lonza Group AG (LZAGY) Q2 2023 Earnings Call Transcript
Lonza Group AG (OTCPK:LZAGY) Q2 2023 Earnings Conference Call July 21, 2023 8:00 AM ET Company Participants Pierre-Alain Ruffieux - CEO Philippe Deecke - CFO Conference Call Participants Richard Vosse...
Lonza: Our Thoughts Pre Capital Market Day, Buy Confirmed
Despite a challenging economic environment, Lonza announced an increase in CAPEX, positioning itself to capture long-term growth opportunities in the healthcare sector. We positively favor Lonza's cap...
Lonza Group AG (LZAGY) Q1 2023 Earnings Call Transcript
Lonza Group AG (OTCPK:LZAGY) Q1 2023 Earnings Conference Call May 9, 2023 9:00 AM ET Company Participants Pierre-Alain Ruffieux - CEO Philippe Deecke - CFO Conference Call Participants Matthew Weston ...
10 Solid Stocks WIth Terrible Tickers
Stocks with long symbols are difficult to remember and easy to overlook. That would be a mistake.
Lonza Group AG (LZAGY) Q4 2022 Earnings Call Transcript
Lonza Group AG (OTCPK:LZAGY) Q4 2022 Earnings Conference Call January 25, 2023 8:00 AM ET Company Participants Pierre-Alain Ruffieux - CEO Philippe Deecke - CFO Conference Call Participants Richard Vo...
Lonza: Positive News From Biogen
No disclosure in Q3, but positive news ahead. Capacity constraint will positively impact Lonza's earnings.
Lonza Group AG (LZAGY) CEO Pierre-Alain Ruffieux on Q2 2022 Results - Earnings Call Transcript
Lonza Group AG (OTCPK:LZAGY) Q2 2022 Earnings Conference Call July 22, 2022 8:00 AM ET Company Participants Pierre-Alain Ruffieux - CEO Philippe Deecke - CFO Conference Call Participants Daniel Buchta...